LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 10 of total 439

Search options

  1. Article ; Online: Triplet Therapy in Metastatic Hormone-Sensitive Prostate Cancer-Calling Out the "Double Standard".

    McHugh, Deaglan J / Scher, Howard I

    JAMA oncology

    2023  Volume 9, Issue 5, Page(s) 617–619

    MeSH term(s) Male ; Humans ; Prostatic Neoplasms/pathology ; Prostatic Neoplasms, Castration-Resistant/pathology ; Hormones ; Androgen Antagonists
    Chemical Substances Hormones ; Androgen Antagonists
    Language English
    Publishing date 2023-02-14
    Publishing country United States
    Document type Editorial ; Comment
    ISSN 2374-2445
    ISSN (online) 2374-2445
    DOI 10.1001/jamaoncol.2023.0324
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

    Inter-library loan at ZB MED

    Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

  2. Article ; Online: Defining new standards of care for men with prostate cancer.

    Scher, Howard I

    Lancet (London, England)

    2016  Volume 387, Issue 10024, Page(s) 1135–1137

    MeSH term(s) Androgen Antagonists/administration & dosage ; Antineoplastic Agents, Hormonal/administration & dosage ; Antineoplastic Combined Chemotherapy Protocols/therapeutic use ; Diphosphonates/administration & dosage ; Humans ; Imidazoles/administration & dosage ; Male ; Prostatic Neoplasms/drug therapy ; Taxoids/administration & dosage
    Chemical Substances Androgen Antagonists ; Antineoplastic Agents, Hormonal ; Diphosphonates ; Imidazoles ; Taxoids ; docetaxel (15H5577CQD) ; zoledronic acid (6XC1PAD3KF)
    Language English
    Publishing date 2016-03-19
    Publishing country England
    Document type Comment ; Journal Article
    ZDB-ID 3306-6
    ISSN 1474-547X ; 0023-7507 ; 0140-6736
    ISSN (online) 1474-547X
    ISSN 0023-7507 ; 0140-6736
    DOI 10.1016/S0140-6736(15)01235-0
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Ua VI Zs.5: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)
    Zs.MG 94: Show issues

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  3. Article ; Online: Optimizing the future: how mathematical models inform treatment schedules for cancer.

    Mathur, Deepti / Barnett, Ethan / Scher, Howard I / Xavier, Joao B

    Trends in cancer

    2022  Volume 8, Issue 6, Page(s) 506–516

    Abstract: For decades, mathematical models have influenced how we schedule chemotherapeutics. More recently, mathematical models have leveraged lessons from ecology, evolution, and game theory to advance predictions of optimal treatment schedules, often in a ... ...

    Abstract For decades, mathematical models have influenced how we schedule chemotherapeutics. More recently, mathematical models have leveraged lessons from ecology, evolution, and game theory to advance predictions of optimal treatment schedules, often in a personalized medicine manner. We discuss both established and emerging therapeutic strategies that deviate from canonical standard-of-care regimens, and how mathematical models have contributed to the design of such schedules. We first examine scheduling options for single therapies and review the advantages and disadvantages of various treatment plans. We then consider the challenge of scheduling multiple therapies, and review the mathematical and clinical support for various conflicting treatment schedules. Finally, we propose how a consilience of mathematical and clinical knowledge can best determine the optimal treatment schedules for patients.
    MeSH term(s) Humans ; Models, Theoretical ; Neoplasms/drug therapy ; Precision Medicine
    Language English
    Publishing date 2022-03-09
    Publishing country United States
    Document type Journal Article ; Review
    ZDB-ID 2852626-0
    ISSN 2405-8025 ; 2405-8033 ; 2405-8033
    ISSN (online) 2405-8025 ; 2405-8033
    ISSN 2405-8033
    DOI 10.1016/j.trecan.2022.02.005
    Database MEDical Literature Analysis and Retrieval System OnLINE

    Full text online

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  4. Article ; Online: Observed Advantages of the STAMPEDE Study Design.

    Scher, Howard I

    European urology

    2015  Volume 67, Issue 6, Page(s) 1039–1041

    MeSH term(s) Androgen Antagonists/therapeutic use ; Humans ; Male ; Neoplasm Metastasis/therapy ; Prostatic Neoplasms/drug therapy ; Taxoids/therapeutic use
    Chemical Substances Androgen Antagonists ; Taxoids
    Language English
    Publishing date 2015-06
    Publishing country Switzerland
    Document type Comment ; Editorial
    ZDB-ID 193790-x
    ISSN 1873-7560 ; 1421-993X ; 0302-2838
    ISSN (online) 1873-7560 ; 1421-993X
    ISSN 0302-2838
    DOI 10.1016/j.eururo.2014.12.004
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 1247: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (1.OG)
    ab Jg. 2022: Lesesaal (EG)
    Zs.MO 294: Show issues

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  5. Article ; Online: Maintaining Bone Health During Hormonal Therapy for Prostate Cancer.

    Farooki, Azeez / Scher, Howard I

    Annals of internal medicine

    2017  Volume 167, Issue 5, Page(s) 357–358

    Language English
    Publishing date 2017-09-05
    Publishing country United States
    Document type Journal Article
    ZDB-ID 336-0
    ISSN 1539-3704 ; 0003-4819
    ISSN (online) 1539-3704
    ISSN 0003-4819
    DOI 10.7326/M17-1800
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Ua VI Zs.178/2: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  6. Article ; Online: Lessons from the SWITCH trial: changing glucocorticoids in the management of metastatic castration-resistant prostate cancer (mCRPC).

    Teo, Min Yuen / Scher, Howard I

    British journal of cancer

    2018  Volume 119, Issue 9, Page(s) 1041–1043

    Abstract: Abiraterone acetate plus prednisone is a standard treatment option for mCRPC. The phase II SWITCH trial showed that further prostate-specific antigen (PSA) responses can be obtained in a subset of patients when prednisone was switched to dexamethasone at ...

    Abstract Abiraterone acetate plus prednisone is a standard treatment option for mCRPC. The phase II SWITCH trial showed that further prostate-specific antigen (PSA) responses can be obtained in a subset of patients when prednisone was switched to dexamethasone at progression. Here, we discuss the potential underlying mechanisms, including the activation of glucocorticoid receptors (GR) in progressive mCRPC and the implications for clinical practice.
    MeSH term(s) Abiraterone Acetate ; Androstenes ; Antineoplastic Combined Chemotherapy Protocols ; Dexamethasone ; Glucocorticoids ; Humans ; Male ; Pilot Projects ; Prednisone ; Prostate-Specific Antigen ; Prostatic Neoplasms, Castration-Resistant
    Chemical Substances Androstenes ; Glucocorticoids ; Dexamethasone (7S5I7G3JQL) ; Prostate-Specific Antigen (EC 3.4.21.77) ; Abiraterone Acetate (EM5OCB9YJ6) ; abiraterone (G819A456D0) ; Prednisone (VB0R961HZT)
    Language English
    Publishing date 2018-10-22
    Publishing country England
    Document type Editorial ; Research Support, N.I.H., Extramural ; Comment
    ZDB-ID 80075-2
    ISSN 1532-1827 ; 0007-0920
    ISSN (online) 1532-1827
    ISSN 0007-0920
    DOI 10.1038/s41416-018-0239-y
    Database MEDical Literature Analysis and Retrieval System OnLINE

    Full text online

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Uh III Zs.142: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  7. Article ; Online: Building on Prostate Cancer Working Group 2 to change the paradigm from palliation to cure.

    Scher, Howard I

    American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting

    2014  , Page(s) e204–12

    Abstract: Developing systemic therapies for advanced prostate cancer has significant challenges, including the difficulty of assessing baseline disease status, disease heterogeneity, and the lack of standards for assessing treatment effects that reliably reflect ... ...

    Abstract Developing systemic therapies for advanced prostate cancer has significant challenges, including the difficulty of assessing baseline disease status, disease heterogeneity, and the lack of standards for assessing treatment effects that reliably reflect clinical benefit. To address these issues, the Prostate Cancer Working Group (PCWG2) took three actions. First, the Group incorporated a prostate cancer clinical states model framework for patient management and drug development. Second was establishing a two-objective paradigm in which trials are designed to evaluate a drug's ability to either (a) control, relieve, or eliminate present disease manifestations or (b) prevent or delay future disease manifestations. Third was the development of consensus criteria for eligibility, outcomes, and reporting in prostate cancer clinical trials. Now that the molecular interrogation of prostate cancer has led to a more complex understanding of disease biology, drug development has transitioned from evaluating cytotoxic agents with activity in multiple tumor types to the rational development of therapies targeting different aspects of the malignant process. In addition, the current availability of multiple therapies for advanced prostate cancer that prolong life brings a new mandate: that we define, validate, and qualify predictive biomarkers of sensitivity to guide treatment selection and establish endpoints short of survival that can lead to drug approval. Optimization of outcomes in future trials will require revised guidance on how to align clinically relevant objectives and eligibility with an evolving disease framework.
    MeSH term(s) Clinical Trials as Topic/standards ; Drug Design ; Drug Therapy/methods ; Humans ; Male ; Patient Selection ; Practice Guidelines as Topic/standards ; Precision Medicine ; Prostatic Neoplasms/drug therapy ; Prostatic Neoplasms/pathology
    Language English
    Publishing date 2014-05-20
    Publishing country United States
    Document type Journal Article ; Research Support, Non-U.S. Gov't ; Review
    ISSN 1548-8756 ; 1092-9118 ; 1548-8748
    ISSN (online) 1548-8756
    ISSN 1092-9118 ; 1548-8748
    DOI 10.14694/EdBook_AM.2014.34.e204
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  8. Article ; Online: Do Patients With AR-V7-Positive Prostate Cancer Benefit from Novel Hormonal Therapies? It All Depends on Definitions.

    Antonarakis, Emmanuel S / Scher, Howard I

    European urology

    2017  Volume 71, Issue 1, Page(s) 4–6

    Language English
    Publishing date 2017-01
    Publishing country Switzerland
    Document type Editorial
    ZDB-ID 193790-x
    ISSN 1873-7560 ; 1421-993X ; 0302-2838
    ISSN (online) 1873-7560 ; 1421-993X
    ISSN 0302-2838
    DOI 10.1016/j.eururo.2016.08.038
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 1247: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (1.OG)
    ab Jg. 2022: Lesesaal (EG)
    Zs.MO 294: Show issues

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  9. Article ; Online: Apalutamide for the treatment of prostate cancer.

    Rathkopf, Dana E / Scher, Howard I

    Expert review of anticancer therapy

    2018  Volume 18, Issue 9, Page(s) 823–836

    Abstract: Introduction: Five new agents have been shown to prolong survival in patients with metastatic castration-resistant prostate cancer, including two targeting androgen receptor signaling (abiraterone acetate plus prednisone; enzalutamide). Recognition that ...

    Abstract Introduction: Five new agents have been shown to prolong survival in patients with metastatic castration-resistant prostate cancer, including two targeting androgen receptor signaling (abiraterone acetate plus prednisone; enzalutamide). Recognition that these tumors remain driven by androgen receptor signaling has prompted clinical evaluation of these agents at earlier states in the prostate cancer disease continuum, along with the continued development of new agents targeting this pathway. Areas covered: This article focuses on apalutamide, a next-generation nonsteroidal antiandrogen, with current literature queried in PubMed/Medline. A narrative review strategy describes studies from engineering of the compound through to a 5-year outlook. Expert commentary: In the phase III SPARTAN study, apalutamide significantly improved metastasis-free survival in patients with nonmetastatic castration-resistant prostate cancer - the first treatment approved by the US Food and Drug Administration for this indication. Phase III studies are under way to determine the clinical benefit of apalutamide in other disease states. Given the multiplicity of prostate cancer treatment options now available, there is a need to maximize individual patient benefit through the development and validation of predictive biomarkers of sensitivity to drugs that can be used in real time to determine the optimal sequence and combinations of treatments for patients in need.
    MeSH term(s) Androgen Receptor Antagonists/administration & dosage ; Androgen Receptor Antagonists/pharmacology ; Animals ; Biomarkers, Tumor/metabolism ; Drug Development/methods ; Humans ; Male ; Neoplasm Metastasis ; Prostatic Neoplasms, Castration-Resistant/drug therapy ; Prostatic Neoplasms, Castration-Resistant/pathology ; Receptors, Androgen/drug effects ; Receptors, Androgen/metabolism ; Survival Rate ; Thiohydantoins/administration & dosage ; Thiohydantoins/pharmacology
    Chemical Substances Androgen Receptor Antagonists ; Biomarkers, Tumor ; Receptors, Androgen ; Thiohydantoins ; apalutamide
    Language English
    Publishing date 2018-08-13
    Publishing country England
    Document type Journal Article ; Research Support, N.I.H., Extramural ; Research Support, Non-U.S. Gov't ; Research Support, U.S. Gov't, Non-P.H.S. ; Review
    ZDB-ID 2112544-2
    ISSN 1744-8328 ; 1473-7140
    ISSN (online) 1744-8328
    ISSN 1473-7140
    DOI 10.1080/14737140.2018.1503954
    Database MEDical Literature Analysis and Retrieval System OnLINE

    Full text online

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 5907: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (2.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  10. Article ; Online: Prognostic and Predictive Value of a Breast Cancer Expression Signature in Localized Prostate Cancer.

    Abida, Wassim / Scher, Howard I

    JAMA oncology

    2017  Volume 3, Issue 12, Page(s) 1673–1674

    MeSH term(s) Androgen Antagonists ; Breast Neoplasms ; Humans ; Male ; Prognosis ; Prostatic Neoplasms ; Receptors, Estrogen
    Chemical Substances Androgen Antagonists ; Receptors, Estrogen
    Language English
    Publishing date 2017-05-10
    Publishing country United States
    Document type Journal Article ; Comment
    ISSN 2374-2445
    ISSN (online) 2374-2445
    DOI 10.1001/jamaoncol.2017.0750
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

    Inter-library loan at ZB MED

    Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

To top